The Long And Winding Road To Mental Health Care For Your Kid

Khn | May 07, 2019

For several months last spring and summer, my teen daughter, Caroline, experienced near-daily bouts of depression and debilitating panic attacks. During those episodes, she became extremely agitated, sobbing uncontrollably and aggressively rebuffing my attempts to comfort or reason with her.

Spotlight

A-Medicare is the innovative path for universal healthcare; a universal health care system that creates affordable healthcare and provides programs using machine learning, artificial intelligence, and blockchain technology via our free platform portal where users gain credits to pay all or some of their health care. A-MEDICARE will be the ULTIMATE DESTINATION


Other News
HEALTH TECHNOLOGY

Cue Health Provides Enhanced Care & Protection for Immunocompromised Populations & Clinical Care Teams at Fresenius Kidney Care

Cue Health Inc. | August 25, 2022

Cue Health Inc. a healthcare technology company announced a new collaboration with Fresenius Kidney Care to provide the most accurate* COVID-19 self-test to certain patients and clinical care teams. People who are immunocompromised have been disproportionately affected by COVID-19 throughout the pandemic and remain highly dependent on measures that reduce the likelihood of infections, including vaccination. Cue can be used by vulnerable patient populations and their care partners to detect and treat COVID-19 early, often before complications arise and hospitalization is required. This is especially important in remote locations where timely and accurate results are critical for making clinical treatment decisions. Fresenius Kidney Care in Hawaii, Alaska, Puerto Rico, Guam, and Saipan will use the Cue Health Monitoring System and Cue COVID-19 Test to screen employees and test symptomatic immunocompromised patients in-center and at-home. "This is a great example of how Fresenius Kidney Care is seeking out the best technologies to ensure we do everything we can to protect our vulnerable patient population from COVID-19," said Ines Dahne-Steuber, President of Spectra Laboratories, a Fresenius Medical Care company providing laboratory diagnostics to dialysis centers across the country. "This collaboration with Cue will help us provide patients with greater access to high-quality timely diagnosis and care in our effort to improve health outcomes while lowering costs." Fresenius Kidney Care operates more than 2,600 dialysis centers in the U.S., providing more than 200,000 patients annually with services that include at-home peritoneal dialysis, at-home hemodialysis, in-center hemodialysis, and additional clinical care resources. "By utilizing Cue's platform, Fresenius Kidney Care can continue to provide its life-saving services to immunocompromised patients with confidence they are using the most accurate COVID-19 self-test. We treat accuracy as non-negotiable so healthcare-affiliated organizations across the country can continue to trust Cue for their testing needs in high-stakes environments." Ayub Khattak, Chairman and CEO of Cue Health Fresenius Kidney Care is one of the growing number of healthcare-affiliated organizations and internationally-recognized hospital systems throughout the U.S working with Cue to transform how diagnostic healthcare is delivered to close gaps in the patient journey and drive improved health outcomes. Cue is used in many other point-of-care settings such as Johns Hopkins Medicine and Mayo Clinic, by world-class organizations across the country, including Google, the National Basketball Association, and Major League Baseball, and in homes. Cue's test uses molecular nucleic acid amplification technology (NAAT) providing lab-quality results directly to connected mobile devices in 20 minutes. The test can detect all known COVID-19 variants and subvariants of concern - including Omicron, BA.4, and BA.5 - and can be used on adults and children (age 2 years and over for over-the-counter (OTC) / home use and under 2 for professional use), with or without symptoms. About Cue Health Cue Health is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care. Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India's Central Drugs Standard Control Organization, and PSAR authorization from Singapore's Health Sciences Authority. Cue was founded in 2010 and is headquartered in San Diego.

Read More

HEALTH TECHNOLOGY

NeuPath Health Unveils Accelerated Growth Plan and Announces Executive Changes

NeuPath Health Inc. | July 26, 2022

NeuPath Health Inc. owner and operator of a network of clinics delivering category-leading chronic pain treatment, announced its strategic growth plan to significantly accelerate the growth of its best-in-class and coordinated continuum of care for patients across Canada who suffer from pain and pain-related musculoskeletal conditions. Chronic pain now impacts 25% of all Canadians at some point in their life and it is often a treatment pathway that is fraught with uncertainty, significant delays and difficulty navigating the system, leading to unsatisfactory outcomes for patients. NeuPath, through its significant number of highly talented, trained and specialized physicians, nurses and staff, along with an important physical footprint across numerous clinics in Ontario and Alberta, intends to expand its geographic reach and the tools available to its teams in order to further deliver the most comprehensive and coordinated treatment solutions for its patients. NeuPath intends to bring to market this expanded and augmented, multi-modal and coordinated treatment through acquisitions, partnering, joint ventures, licensing or other business arrangements that provide NeuPath’s patients with best-in-class, outcomes-driven solutions. By offering a full and coordinated spectrum of care and with easier navigation for patients, NeuPath’s patients will lead lives more fully lived. About NeuPath NeuPath is a vertically integrated health care provider utilizing research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by chronic pain, spinal injuries, sport-related injuries, and concussions. With equity ownership in seventeen clinics in Ontario and Alberta, NeuPath is building out a large-scale network to better serve patients across Canada. NeuPath is focused on transforming the hope of a better life into the reality of a life more fully lived.

Read More

FUTURE OF HEALTHCARE

Athlete Training and Health Expands with New Facilities, Team Members

Athlete | September 27, 2022

Whether for active adults or Olympians, Athlete Training and Health (ATH) encourages its athletes to strive for their own personal best. ATH is raising its own bar on community health and performance training once again, with the announcement of two new facilities in the Houston area and the addition of another world-renowned coach to its executive staff. “What we know is that evidence-led training allows everyone to benefit from the science behind the best in health and performance. Expanding and offering this world-class environment and approach will benefit athletes of all ages and abilities. We are pleased to collaborate with healthcare systems, professional sports teams, universities and school districts to continue pursuing a new level of health and performance training for many communities.” Greg Centilli, chief operating officer for ATH and a recent addition to the growing ATH organization Construction has begun on a new ATH sports medicine and human performance facility in Pearland. Located on the Memorial Hermann Pearland Hospital campus at 16100 South Freeway, the roughly 13K-square-foot facility will house unparalleled human performance expertise and opportunities to train in an adult fitness space, a professional sport-style weight room, and on indoor and outdoor turf fields. The facility, a collaboration between ATH, Memorial Hermann and UT Physicians Orthopedics, is expected to open fall 2023. Also in the works is an ATH facility in Cypress, also in collaboration with Memorial Hermann. On the campus of Memorial Hermann Cypress Hospital at 27800 Highway 290, ATH will open and operate a roughly 13K-square-foot facility in 2024. At this location, student, collegiate, professional and adult athletes will find the expertise needed to up their game on their own performance. “We are extremely pleased to welcome Professor Cronin to ATH. His science-based expertise and educational experience, alongside his international standing, will help educate investors and the general markets on the significance and industry importance of ATH-led initiatives,” said Centilli. Cronin serves as professor of strength and conditioning at the Sports Performance Research Institute of New Zealand (SPRINZ) at Auckland University of Technology (AUT). His research interests are in human movement, particularly around strengthening of muscle, injury resistance, return to play and high-performance sports. Cronin’s research has been published in more than 400 peer-reviewed papers. AUT and ATH have a long-standing history. Post-graduate fellows from AUT conduct research at ATH as part of a team involving coaches and select students, as well as collaborate on sport technology development. “I know the organization well, and my research interests and expertise align well with ATH’s interest in sporting performance and allied health, so I’m very excited to be advising ATH about the latest science-based studies and learnings to support their people, programs and products,” Cronin said. Celebrating Wins While its clients celebrate personal victories, ATH celebrates industry wins. Readers of Living Magazine recently voted ATH the “2022 Best Health Club/Gym” winner in McKinney/Allen and in Katy/Fulshear via an annual award competition that allows readers to nominate and then vote for their favorite companies by category and market. ATH also was honored to be named a “2022 Neighborhood Favorite” in NextDoor’s annual celebration of local businesses, and a finalist for “2022 Best Gym/Fitness Center in Houston” by readers of Houston Chronicle in an annual awards competition voted on by Houstonians. “While it’s important for us to acknowledge the hard work of our coaches and staff who make awards like these possible, it’s our job to continuously raise the bar, so we consider this just the beginning,” noted Centilli. “We are excited about what we have accomplished and are even more excited for the developments ahead.” Whether it’s losing the pandemic pounds, living in a healthier body, or even reaching the pinnacle of your sport, the certified, experienced sports performance experts at ATH have the expertise and a program tailored just for you. ABOUT ATHLETE TRAINING AND HEALTH (ATH) ATH is more than a gym. It’s a place of community, inspiration and results. ATH provides award-winning adult fitness and sports performance training for youth, collegiate and professional athletes. ATH utilizes best practices from human performance research to provide a world-class training environment for athletes and adults of all fitness levels collaborating with hospitals, professional sports teams, universities and school districts to set new standards for health and performance training. ATH invests heavily in the post-graduate education of its performance coaches, who in turn develop evidence-led training programs guaranteed to deliver sustainable results. ATH currently operates two training centers in the Houston metro area and one in Allen, north of DFW.

Read More

HEALTH TECHNOLOGY

CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

Pulmonx Corporation | September 05, 2022

Pulmonx Corporation a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the collateral ventilation status in 78% of patients who were subsequently treated with Zephyr Valves. The AeriSeal System is used to close collateral air channels in a target lung lobe of a patient with severe COPD/emphysema, making the patient eligible to then undergo Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Valves. Patients whose lungs have untreated collateral ventilation are currently ineligible for treatment with Zephyr Valves and have limited options once medical management alone does not control symptoms. Once the target lobe is converted from CV+ to CV-, patients can be treated with Zephyr Valves, which has been shown to improve lung function, quality of life, and exercise capacity for patients with severe COPD/emphysema. The CONVERT study uses the AeriSeal System to close collateral air flow. Once the treated lobe tests negative for collateral ventilation Zephyr Valves are implanted to address hyperinflation of that target lobe to ease emphysema symptoms without major surgery. Successfully converted patients who received Zephyr Valves had clinically meaningful Target Lobe Volume Reduction with a mean reduction of greater than one (1) liter. The CONVERT trial is ongoing and full clinical outcomes of BLVR with Zephyr Valves were not reported at this time. However, results recently published from a single-center feasibility study at Macquarie University Hospital in Australia showed that the AeriSeal System successfully closed collateral air channels and allowed for successful clinical outcomes after treatment with Zephyr Valves.2 At 6 months, AeriSeal and Zephyr Valve treated CV+ patients experienced clinically meaningful improvements similar to improvements in CV- patients treated with Zephyr Valves alone.2 Improvements included Lung function (FEV1 increase of 19.7%, Residual Volume decrease of 16.2%) Quality of life (SGRQ score decrease of 15.1 points) Exercise capacity (Six-Minute Walk Distance increase of 77.2 meters) There were no serious adverse reactions experienced by patients in the Australian feasibility study; 20% of patients in the CONVERT Study experienced an inflammatory response following AeriSeal treatment - all were transient, medically managed, and resolved. The available data suggest that patients with collateral ventilation can undergo successful BLVR with Zephyr Valves following closure of the fissure gap with the AeriSeal System. “This is very promising news for patients with advanced COPD. We know that treatment with Zephyr Valves can provide long-term improvements in lung function, breathing, and quality of life, but for patients with collateral ventilation, this minimally invasive treatment has not been available as an option,” explains Dr. Michela Bezzi, Department Head and Director Interventional Pulmonology - ASST Spedali Civili, University Hospital, Brescia, Italy. “Having a technology like the AeriSeal System to convert collateral ventilation positive patients to negative status means we can provide a treatment to patients who currently have very few options.” “This work reflects our continued commitment to developing and testing new medical technologies to help patients with severe lung disease breathe easier and have better quality of life. These early study results are encouraging and move us closer to the goal of helping severe emphysema patients who have collateral ventilation benefit from our proven Zephyr Valve treatment.” Glen French, President and Chief Executive Officer of Pulmonx About the CONVERT Study CONVERT is a prospective, open-label, multi-center, single-arm study being conducted at up to 20 investigational sites. The study plans to enroll 140 subjects with severe emphysema and collateral ventilation in the target lobe. This protocol is designed to evaluate the utility of the AeriSeal System, which uses a synthetic polymer foam to occlude collateral air channels in a target lung lobe and convert the target lung lobe to having little to no collateral ventilation. Patients will then undergo Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves. Zephyr Valves are not effective if collateral ventilation (CV+) is present but once the target lobe is converted from CV+ to CV-, patients can be treated with Zephyr Valves which has been shown to improve lung function, quality of life, and exercise capacity for patients with severe COPD/emphysema. About Zephyr Valves The Zephyr Valve is a minimally invasive treatment option for severe COPD/emphysema. Zephyr Valves are placed via bronchoscopy to block off a diseased portion of the lung to prevent air from getting trapped and reduce hyperinflation, which allows the healthier lung tissue to expand and take in more air. This results in patients being able to breathe easier, be less short of breath, and have an improvement in their quality of life.1 National and global treatment guidelines for COPD include Endobronchial Valves like Zephyr Valves with the Global Initiative for Chronic Obstructive Lung Disease giving valves an ‘Evidence A’ rating. More than 25,000 patients have been treated with the Zephyr Valve worldwide. About Pulmonx Corporation Pulmonx Corporation is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who, despite medical management, are still profoundly symptomatic. Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients.

Read More

Spotlight

A-Medicare is the innovative path for universal healthcare; a universal health care system that creates affordable healthcare and provides programs using machine learning, artificial intelligence, and blockchain technology via our free platform portal where users gain credits to pay all or some of their health care. A-MEDICARE will be the ULTIMATE DESTINATION

Resources